Drug Interactions and Polypharmacy in Psychopharmacology

MAOIs can interact with tricyclic antidepressants, leading to a hypertensive crisis due to the accumulation of norepinephrine and serotonin.

Polypharmacy refers to the simultaneous use of multiple medications to treat a single condition.

The combination of MAOIs and SSRIs can lead to serotonin syndrome, a potentially life-threatening condition characterized by hyperthermia, agitation, and muscle rigidity.

Cytochrome P450 enzymes primarily metabolize drugs through oxidation reactions.

Phenobarbital is a potent inducer of cytochrome P450 enzymes, which can lead to increased metabolism and decreased effectiveness of other drugs.

A pharmacokinetic interaction occurs when one drug alters the absorption, distribution, metabolism, or excretion of another drug, leading to changes in its concentration and effectiveness.

Erythromycin is a potent inhibitor of cytochrome P450 enzymes, which can lead to increased concentrations and toxicity of other drugs metabolized by these enzymes.

A pharmacodynamic interaction occurs when one drug alters the response of the body to another drug, leading to changes in its effectiveness.

The combination of carbamazepine and phenytoin can increase the risk of seizures due to their additive effects on lowering the seizure threshold.

Combination therapy involves the use of two or more drugs with different mechanisms of action to achieve a synergistic effect.

The combination of lithium and haloperidol can increase the risk of QT prolongation and torsades de pointes, potentially leading to cardiac arrhythmias.

Augmentation therapy involves the use of a drug to reduce or eliminate the adverse effects of another drug.

The combination of antipsychotics and lithium can increase the risk of neuroleptic malignant syndrome (NMS), a potentially life-threatening condition characterized by hyperthermia, muscle rigidity, and altered mental status.

Augmentation therapy involves the use of a drug to enhance the effectiveness of another drug.

The combination of antipsychotics and lithium can increase the risk of tardive dyskinesia (TD), a movement disorder characterized by involuntary muscle movements.